First-in-Human Study of TAK-280 in Participants With Solid Tumors

NCT05220098 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

69

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated due to limited anti-cancer activity

Conditions

Unresectable Locally Advanced or Metastatic Cancer

Interventions

DRUG: TAK-280

Sponsor

Takeda

Collaborators

[object Object]